Morten B. Ladekarl
Distinguished in Pancreatic Cancer

Morten B. Ladekarl

Aalborg, DK 
Distinguished in Pancreatic Cancer
Aalborg, DK 
OverviewLocationsClinical Research

Overview

Morten Ladekarl practices in Aalborg, Denmark. Mr. Ladekarl is rated as a Distinguished expert by MediFind in the treatment of Pancreatic Cancer. His top areas of expertise are Pancreatic Cancer, Neuroendocrine Tumor, Merkel Cell Carcinoma, Hepato-Pancreato-Biliary Surgery, and Pancreatectomy.

His clinical research consists of co-authoring 74 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 28 articles and participated in 1 clinical trial in the study of Pancreatic Cancer.

Gender
Male

Locations

Aalborg, Denmark
Other Locations
Gistrup, 9260, Denmark
Arhus, Denmark
Aarhus C, Denmark
Roskilde, Denmark

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Randomized Open Label Study to Compare the Efficacy and Safety of Everolimus Followed by Chemotherapy With Streptozotocin- Fluorouracilo (STZ-5FU) Upon Progression or the Reverse Sequence, in Advanced Progressive Pancreatic NETs (pNETs)
Randomized Open Label Study to Compare the Efficacy and Safety of Everolimus Followed by Chemotherapy With Streptozotocin- Fluorouracilo (STZ-5FU) Upon Progression or the Reverse Sequence, in Advanced Progressive Pancreatic NETs (pNETs)
Enrollment Status: Completed
Publish Date: May 11, 2025
Intervention Type: Drug
Study Drug: STZ-5FU
Study Phase: Phase 3
Chemotherapy for Patients With Locally Advanced Pancreatic Cancer With Additional Chemo-radiotherapy for Patients With Borderline Resectable Tumours
Chemotherapy for Patients With Locally Advanced Pancreatic Cancer With Additional Chemo-radiotherapy for Patients With Borderline Resectable Tumours
Enrollment Status: Completed
Publish Date: November 02, 2020
Intervention Type: Drug
Study Phase: Phase 2
Dose Determination of Taxotere®, Eloxatin® and Xeloda® (TEX)in Combination With Herceptin® as First-line Treatment for Patients With HER2 Positive Non-resectable Oesophagus, Cardia or Gastric Cancer (ECV)
Dose Determination of Taxotere®, Eloxatin® and Xeloda® (TEX)in Combination With Herceptin® as First-line Treatment for Patients With HER2 Positive Non-resectable Oesophagus, Cardia or Gastric Cancer (ECV)
Enrollment Status: Completed
Publish Date: November 02, 2020
Intervention Type: Drug
Study Phase: Not Applicable
View 2 Less Clinical Trials

72 Total Publications

Pembrolizumab treatment of prostate cancer
Pembrolizumab treatment of prostate cancer
Journal: Ugeskrift for laeger
Published: November 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ladekarl's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile